Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer, James F. Blake, Karyn Bouhana, David M. Briere, Karin Brown, Laurence E. Burgess, Aaron C. Burns, Michael Burkard, Harrah Chiang, Mark J. Chicarelli, Adam W. Cook, John J. Gaudino, Jill Hallin, Lauren Hanson, Dylan P. Hartley, Erik J. Hicken, Gary P. Hingorani, Ronald J. Hinklin, Macedonio J. Mejia, Peter Olson, Jennifer Otten, Susan P. Rhodes, Martha E. Rodriguez, Pavel Y. Savechenkov, Darin Smith, Niranjan Sudhakar, Francis X. Sullivan, Tony P. Tang, Guy Vigers, Lance Wollenberg, James G. Christensen, Matthew A. Marx